Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06165419 · ClinicalTrials.gov registry record · Phase 2
Definitive Radiation for High-Risk Spine Metastases
A Phase 2 study of Metastatic Breast Cancer and Metastatic Cancer, sponsored by Stony Brook University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT06165419: Recruiting Phase 2 study of Metastatic Breast Cancer and Metastatic Cancer, sponsored by Stony Brook University.
NCT06165419 is a Phase 2 study of Metastatic Breast Cancer and Metastatic Cancer that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 26 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06165419, a Phase 2 study of Metastatic Breast Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery
Primary Outcome
Assess the efficacy of spine SBRT alone in controlling spine metastases
Conditions Studied
Interventions
- RADIATION SBRT to the spine
Study Locations (1)
New York
- Stony Brook University Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
What NCT06165419 shows while recruiting
NCT06165419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (87% lower).
The record links to 8 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which SBRT to the spine is the first listed.
NCT06165419 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06165419 about?
NCT06165419 is a clinical study titled "Definitive Radiation for High-Risk Spine Metastases". This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery
What is the current status of trial NCT06165419?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2023-12-14. Estimated completion is 2026-05-31.
What conditions does trial NCT06165419 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Metastatic Cancer, Metastasis, Metastatic Lung Cancer, Spine Metastases.
What interventions are being tested in trial NCT06165419?
The interventions under investigation include: SBRT to the spine (RADIATION).
Who is sponsoring clinical trial NCT06165419?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06165419 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06165419's enrollment target sits among peer trials
26 113th of 139 higher than 27 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI